Pliant Therapeutics (NASDAQ:PLRX) Sets New 1-Year Low at $12.35

Pliant Therapeutics, Inc. (NASDAQ:PLRX) reached a new 52-week low during trading on Thursday . The stock traded as low as $12.35 and last traded at $12.45, with a volume of 15312 shares changing hands. The stock had previously closed at $12.86.

Analyst Ratings Changes

Several equities research analysts have recently commented on PLRX shares. HC Wainwright reissued a “buy” rating and issued a $48.00 price objective on shares of Pliant Therapeutics in a report on Wednesday, February 28th. Needham & Company LLC reaffirmed a “buy” rating and set a $38.00 price target on shares of Pliant Therapeutics in a report on Wednesday, April 10th. Finally, Royal Bank of Canada raised their price target on Pliant Therapeutics from $50.00 to $54.00 and gave the company an “outperform” rating in a report on Tuesday, March 5th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Pliant Therapeutics presently has an average rating of “Buy” and a consensus target price of $49.00.

Pliant Therapeutics Stock Up 2.7 %

The company has a current ratio of 17.72, a quick ratio of 17.72 and a debt-to-equity ratio of 0.02. The stock has a market cap of $754.20 million, a P/E ratio of -4.49 and a beta of 1.12. The firm has a 50-day simple moving average of $15.15 and a two-hundred day simple moving average of $15.67.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. BlackRock Inc. increased its position in shares of Pliant Therapeutics by 141.1% in the second quarter. BlackRock Inc. now owns 4,406,820 shares of the company’s stock worth $79,852,000 after purchasing an additional 2,578,692 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of Pliant Therapeutics by 13.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,785,916 shares of the company’s stock worth $68,564,000 after purchasing an additional 434,429 shares during the period. First Light Asset Management LLC increased its position in shares of Pliant Therapeutics by 22.4% in the fourth quarter. First Light Asset Management LLC now owns 3,591,776 shares of the company’s stock worth $65,047,000 after purchasing an additional 658,516 shares during the period. Laurion Capital Management LP increased its position in shares of Pliant Therapeutics by 0.9% in the third quarter. Laurion Capital Management LP now owns 3,186,511 shares of the company’s stock worth $55,254,000 after purchasing an additional 27,941 shares during the period. Finally, Vanguard Group Inc. increased its position in shares of Pliant Therapeutics by 4.1% in the fourth quarter. Vanguard Group Inc. now owns 3,065,869 shares of the company’s stock worth $55,523,000 after purchasing an additional 120,557 shares during the period. Institutional investors own 97.30% of the company’s stock.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.